Review Article

Definition, Etiology, Pathophysiology and Management of Liver Cirrhosis

Gudisa Bereda 

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia

Corresponding Author: Gudisa Bereda, Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia. Tel: +251913118492/+251919622717, Email: [email protected] 

Received: September 21, 2022                                  Published: October 01, 2022 

Citation: Gudisa B. Definition, Etiology, Pathophysiology and Management of Liver Cirrhosis. Int J Complement Intern Med. 2022;1(1):5–11. 

Copyright: ©2022 Bereda. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Abstract 

Cirrhosis can be defined histologically as a diffuse process in which the normal anatomical lobules are replaced by architecturally abnormal nodules separated by fibrous tissue. Stage 3 cirrhosis encloses the advancement of swelling in the abdomen and advanced liver scarring. The etiology of cirrhosis differs based on geographically, with alcoholism, chronic hepatitis C virus infection, and nonalcoholic fatty lives disease being the consummate ubiquitous causes in western countries, whereas chronic hepatitis B is the initial cause of liver cirrhosis. The transition from chronic liver disease to cirrhosis encloses inflammation, initiation of hepatic stellate cells with following fibrogenesis, angiogenesis, and parenchymal extinction lesions caused by vascular occlusion. Only abstinence from alcohol ameliorates survival in alcoholic cirrhosis. Treatment of the underlying disease can frequently impasse or even reverse the progression of earlystage cirrhosis. The mainstay of primary prophylaxis is the use of nonselective β-adrenergic blocking agents such as propranolol or nadolol. Somatostatin and octreotide cause a reduction in portal pressure and port-collateral blood flow through inducing splanchnic vasoconstriction without causing the systemic effects consociated with vasopressin. Prophylactic antibiotic therapy should be prescribed for all patients with cirrhosis and acute variceal bleeding. 

Keywords: Definition, Etiology, Liver Cirrhosis, Pathophysiology, Management

References 

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51. 

2. Dooley J, Lok A, Burroughs AK, eds. Sherlock’s diseases of the liver and biliary system, 12th edn. Oxford: Wiley–Blackwell. 2011. 

3. Garcia Tsao G, Friedman S, Iredale J, et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445–1449. 

4. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol. 2007;292:G518–525. 

5. Keshavarzian A, Farhadi A, Forsyth CB, et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol. 2009;50:538–547. 

6. Naveau S, Perlemuter G, Balian A. Epidemiology and natural history of cirrhosis. Rev Prat. 2005;55:1527– 1532. 

7. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31: 1014–1018. 

8. Innes HA, Hutchinson SJ, Barclay S, et al. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost–effectiveness. Hepatology. 2013;57:451– 460. 

9. Ganem D, Prince AM. Hepatitis B virus infection— natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129. 

10. Lv GC, Yao JM, Yang YD, et al. Efficacy of combined therapy in patients with hepatitis B virus–related decompensated cirrhosis. World J Gastroenterol. 2013;19:3481–3486. 

11. Liaw YF, Leung N, Kao JH, et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283. 

12. Britton RS, Brown KE. Genetic hemochromatosis and Wilson’s disease: role for oxidant stress? Hepatology. 1995;21:1195–1197. 

13. Olynyk JK, Trinder D, Ramm GA, et al. Hereditary hemochromatosis in the post–HFE era. Hepatology. 2008;48:991–1001. 

14. Camaschella C. Treating iron overload. N Engl J Med. 2013;368:2325–2327. 

15. Dowling D. Screening for Wilson’s disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2009;50:329. 

16. Deutsch M, Emmanuel T, Koskinas J. Autoimmune Hepatitis or Wilson’s Disease, a Clinical Dilemma. Hepat Mon. 2013;e7872. 

17. Wu SJ, Yang YH, Tsuneyama K, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology. 2011;53:915–925. 

18. van Os E, van den Broek WW, Mulder PG, et al. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007;46:1099–1103. 

19. Popov Y. Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet? Hepatology. 2013;57:429–431. 20. Selmi C, Bowlus CL, Gershwin ME. Primary biliary cirrhosis. Lancet. 2011;377:1600–1609. 

21. Poupon R, Chazouilleres O, Corpechot C. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85–90. 

22. Schuppan D, Nezam H Afdhal. Liver Cirrhosis. Lancet. 2008;371(9615):838–851. 

23. Emmanuel A Tsochatzis, Jaime Bosch, Andrew K Burroughs. Liver cirrhosis. Lancet. 2014. 

24. Wanless IR, Wong F, Blendis LM. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238–1247. 

25. Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol. 2009;50:604–620. 

26. García Pagán JC, Gracia Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57:458–461. 

27. Romanelli RG, Stasi C. Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis. Current Drug Targets. 2016;17(12). 

28. Crawford JM, Burt AD. Anatomy, pathophysiology, and basic mechanisms of disease. In: Burt AD, Portmann B, Ferrell LD (Eds) MacSween’s Pathology of the liver, 6th ed, Philadelphia, PA: Churchill Livingstone; 2012:1–78. 

29. Minano C, Garcia Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am 2010;39:681–695. 

30. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478–491. 

31. Wiechowska A, McCullough AJ, Feldstein AE. Non– invasive diagnosis and monitoring of non–alcoholic steatohepatitis: present and future. Hepatology. 2007;46:582–589. 

32. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413–419. 

33. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108– 111. 

34. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Metabolic syndrome is associated with severe fi brosis in chronic viral hepatitis and non–alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;27:80–89. 

35. Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12–month trial. Hepatology. 2008;48:557–566. 

36. Luca A, García Pagán JC, Bosch J, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology. 1997;112:1284–1289. 

37. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399–420. 

38. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fi brosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat. 2002;9:235–241. 

39. Forner A, L lovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. 40. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972– 1978. 

41. Moriarty K, Cassidy P, Dalton D, et al. Alcohol related disease: meeting the challenge of improved quality of care and better use of resources. 2013. 

42. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology. 2012;56:1983–1992. 

43. Zein CO. Clearing the smoke in chronic liver diseases. Hepatology. 2010;51:1487–1490. 

44. Hézode C, Roudot Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42:63–71. 

45. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long term therapy with adefovir dipivoxil for HBeAg–negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751. 

46. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B. A 5 year open label follow up study. Lancet. 2013;381:468–475. 

47. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669. 

48. de Franchis R, Baveno V. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–768. 

49. Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38 266–272. 

50. Garcia Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010; 362:823–832. 

51. Groszmann RJ, Garcia Tsao G, Bosch J, et al. Beta blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–2261. 

52. Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood fl ow and hepatic and systemic hemodynamics in cirrhosis. Hepatology. 1984;4:1200–1205. 

53. Andreu V, Perello A, Moitinho E, et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol. 2002;36:356–361. 

54. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51:2214–2218. 

55. Burroughs AK, Tsochatzis EA, Triantos C. Primary prevention of variceal haemorrhage: a pharmacological approach. J Hepatol. 2010;52:946–948. 

56. Bañares R, Albillos A, Rincón D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta– analysis. Hepatology. 2002;35:609–615. 

57. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet. 1999;353:139–142. 

58. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004;39:746–753. 

59. Gonzalez R, Zamora J, Gomez Camarero J, et al. Meta analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149:109–122.